Comparing SG&A Expenses: GSK plc vs Exelixis, Inc. Trends and Insights

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants like GSK plc and emerging players such as Exelixis, Inc. is crucial. From 2014 to 2023, GSK plc consistently reported higher Selling, General, and Administrative (SG&A) expenses compared to Exelixis, Inc., reflecting its expansive global operations. GSK's expenses peaked in 2020, reaching nearly 11.5 billion, before slightly declining. In contrast, Exelixis, Inc. demonstrated a remarkable growth trajectory, with SG&A expenses increasing by over 900% from 2014 to 2023, highlighting its aggressive expansion and investment in market presence. This comparison not only underscores the scale of GSK's operations but also showcases Exelixis's rapid growth and strategic investments. As the pharmaceutical industry continues to innovate, these financial insights provide a window into the strategic priorities of these companies.